Get notified when SXTC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Vie Agreements (new) — The company's control over its main operating entity rests on untested contractual arrangements, so investors may not have enforceable ownership of the underlying business.
China SXT Pharmaceuticals launches $100M at-the-market offering of Class A shares at $1.65
Filed June 1, 2026 · ~1 min read
Key Changes
-
high
The company may sell up to $100 million of Class A Ordinary Shares from time to time through an at-the-market program with Univest as sales agent.
Use of Proceeds verify on EDGAR → -
high
Investors in this offering face immediate dilution of $0.33 per share, with pro forma net tangible book value at $1.32 after the offering.
Dilution verify on EDGAR → -
medium
Net proceeds are earmarked for general corporate purposes, including operating expenses, capital expenditures, potential acquisitions, and business development.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
Partner
Trade SXTC commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify